Ferrer Internacional
Ferrer Internacional is a privately-held European research and development-based pharmaceutical company based in Barcelona. It operates across various sectors, including pharmaceuticals, health, fine chemicals, and food, with a presence in Europe, Latin America, Africa, the Middle East, Asia, and the United States. Ferrer’s healthcare products are marketed in over 95 countries through 24 international affiliates and numerous partners and distributors. The company is engaged in the entire pharmaceutical value chain, encompassing research and development, international marketing, and the manufacturing of both raw materials and finished products. Its portfolio includes prescription drugs, vaccines, personalized medicines, hospital equipment, and consumer healthcare products. Ferrer maintains research centers in Spain and Germany, as well as manufacturing facilities in Europe and Latin America, which support its diverse operations in pharmaceuticals, diagnostics, and fine chemicals.
ABAC Therapeutics S.A. develops precision antimicrobial agents for precision treatment of MDR Gram-negative infections. It offers PasNas, a drug discovery platform unveiling pathogen-specific antibacterial properties of molecules while promoting the compounds active against MDR strains with new mechanism of action and with maximized chances of success in clinical development. The company was incorporated in 2014 and is based in Barcelona, Spain. As of November 20, 2019, ABAC Therapeutics S.A. operates as a subsidiary of Tibidabo Ventures.
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions.
It was founded in 2001 and headquartered in Mountain View, California.
Venter Pharma SL, a biotech company, develops diagnostic drugs for the diagnosis of lactose intolerance. It develops LacTEST, a diagnostic drug that helps professionals to manage the lactose intolerance disease. Venter Pharma SL was formerly known as Lactest SL. The company was founded in 2003 and is based in Alcobendas, Spain.
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for oncology and central nervous system (CNS) disorders. The company is recognized as a leader in this field in Europe, focusing on personalized medicine approaches. Its key clinical candidates include iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor undergoing Phase II trials for CNS and psychiatric conditions. Additionally, Oryzon is developing ORY-3001, another LSD1 inhibitor in preclinical stages for non-oncological diseases, along with other programs in various development phases. Founded in 2000, Oryzon Genomics is committed to advancing innovative treatments through its research in epigenetic medicine.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.